Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

New-onset IgG autoantibodies in hospitalized patients with COVID-19.

Sarah Esther Chang | Allan Feng | Wenzhao Meng | Sokratis A Apostolidis | Elisabeth Mack | Maja Artandi | Linda Barman | Kate Bennett | Saborni Chakraborty | Iris Chang | Peggie Cheung | Sharon Chinthrajah | Shaurya Dhingra | Evan Do | Amanda Finck | Andrew Gaano | Reinhard Geßner | Heather M Giannini | Joyce Gonzalez | Sarah Greib | Margrit Gündisch | Alex Ren Hsu | Alex Kuo | Monali Manohar | Rong Mao | Indira Neeli | Andreas Neubauer | Oluwatosin Oniyide | Abigail E Powell | Rajan Puri | Harald Renz | Jeffrey Schapiro | Payton A Weidenbacher | Richard Wittman | Neera Ahuja | Ho-Ryun Chung | Prasanna Jagannathan | Judith A James | Peter S Kim | Nuala J Meyer | Kari C Nadeau | Marko Radic | William H Robinson | Upinder Singh | Taia T Wang | E John Wherry | Chrysanthi Skevaki | Eline T Luning Prak | Paul J Utz
Nature communications | 2021

COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.

Pubmed ID: 34521836 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: L40 AI120105
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI125197
  • Agency: NIAID NIH HHS, United States
    Id: UM1 AI144292
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI117950
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI082630
  • Agency: NIAID NIH HHS, United States
    Id: P01 AI112521
  • Agency: NCI NIH HHS, United States
    Id: P30 CA016520
  • Agency: NIDDK NIH HHS, United States
    Id: UC4 DK112217
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI111825
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI105343
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI139119
  • Agency: NIAMS NIH HHS, United States
    Id: T32 AR076951
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI123539
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI104209
  • Agency: NIAID NIH HHS, United States
    Id: UM2 AI130836
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL137006
  • Agency: NCI NIH HHS, United States
    Id: U54 CA260517
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL137915
  • Agency: NHLBI NIH HHS, United States
    Id: T32 HL007586
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI057229
  • Agency: NIAID NIH HHS, United States
    Id: UM1 AI144288
  • Agency: NIAID NIH HHS, United States
    Id: P30 AI045008
  • Agency: NIAID NIH HHS, United States
    Id: UM1 AI130839
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI150741

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HEp-2 (tool)

RRID:CVCL_1906

Cell line HEp-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions